Vaccine adjuvant formulations: A pharmaceutical perspective

Seminars in Immunology

Volumn 25, Issue 2, 2013, Pages 130-145

  Brito, Luis A ^a   Malyala, Padma ^a   O'Hagan, Derek T ^a  

^a Novartis Vaccines Cambridge   (United States)

Author keywords

Adjuvant; Alum; Emulsion; Formulations; PLG; Vaccine

Indexed keywords

ADJUVANT; ALPHA TOCOPHEROL; ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; ALUMINUM POTASSIUM SULFATE; ALUMINUM SALT; CLEVIDIPINE; DIAZEPAM; ETOMIDATE; FLUOSOL DA; HYDROXYL GROUP; INFLUENZA VACCINE; INTRALIPID; ISCOM; LIPOPROSTAGLANDIN E1; LIPOSOME; LIPOSYN II; MIFAMURTIDE; PHOSPHOLIPID; POLYMER; PROPOFOL; SOYBEAN OIL EMULSION; SQUALENE; TOLL LIKE RECEPTOR AGONIST; VACCINE; WART VIRUS VACCINE;

ADSORPTION KINETICS; BINDING AFFINITY; CHEMICAL STRUCTURE; DIFFERENTIAL SCANNING CALORIMETRY; EMULSION; EXCIPIENT COMPATIBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERBARISM; IMMUNIZATION; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; INNATE IMMUNITY; IONIC STRENGTH; LIPOSOMAL DELIVERY; MASS SPECTROMETRY; NARCOLEPSY; NUCLEAR MAGNETIC RESONANCE; PATHOGENICITY; PH; PROTEIN ANALYSIS; REVIEW; RISK BENEFIT ANALYSIS; STATIC ELECTRICITY; TEMPERATURE; VIRUS LIKE AGENT; X RAY POWDER DIFFRACTION;

ADJUVANT; ALUM; EMULSION; FORMULATIONS; PLG; VACCINE;

ADJUVANTS, PHARMACEUTIC; ANIMALS; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; VACCINES;

EID: 84882246220     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2013.05.007     Document Type: Review

References (123)

1. Chase H.P., Beck R.W., Xing D., Tamborlane W.V., Coffey J., Fox L.A., et al. Continuous glucose monitoring in youth with type 1 diabetes: 12-month follow-up of the Juvenile Diabetes Research Foundation continuous glucose monitoring randomized trial. Diabetes Technology & Therapeutics 2010, 12:507-515.
2. Roldao A., Mellado M.C., Castilho L.R., Carrondo M.J., Alves P.M. Virus-like particles in vaccine development. Expert Review of Vaccines 2010, 9:1149-1176.
3. Bachmann M.F., Jennings G.T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nature Reviews Immunology 2010, 10:787-796.
4. Bachmann M.F., Rohrer U.H., Kundig T.M., Burki K., Hengartner H., Zinkernagel R.M. The influence of antigen organization on B cell responsiveness. Science 1993, 262:1448-1451.
5. Lousada-Dietrich S., Jogdand P.S., Jepsen S., Pinto V.V., Ditlev S.B., Christiansen M., et al. A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2 - a GLURP-MSP3 fusion protein malaria vaccine candidate. Vaccine 2011, 29:3284-3292.
6. Fox C.B., Huynh C., O'Hara M.K., Onu A. Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania. Vaccine 2013, 31(12):1633-1640.
7. Fukata M., Vamadevan A.S., Abreu M.T. Toll-like receptors (TLRs) and Nod-like receptors (NLRs) in inflammatory disorders. Seminars in Immunology 2009, 21:242-253.
8. Fox C.B., Baldwin S.L., Vedvick T.S., Angov E., Reed S.G. Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines. Clinical and Vaccine Immunology 2012, 19:1633-1640.
9. Klinman D.M. Adjuvant activity of CpG oligodeoxynucleotides. International Reviews of Immunology 2006, 25:135-154.
10. Ayas N.T., Fox J., Epstein L., Ryan C.F., Fleetham J.A. Initial use of portable monitoring versus polysomnography to confirm obstructive sleep apnea in symptomatic patients: an economic decision model. Sleep Medicine 2010, 11:320-324.
11. O'Hagan D. New generation vaccine adjuvants 2007.
12. Russell G.N., Desmond M.J., Fox M.A. Local anesthesia for radial artery cannulation: a comparison of a lidocaine-prilocaine emulsion and lidocaine infiltration. Journal of Cardiothoracic Anesthesia 1988, 2:309-312.
13. Kim A., Dombi E., Solomon J., Fox E., Balis F.M., Widemann B.C. Automated volumetric growth plate measurement using magnetic resonance imaging for monitoring skeletal toxicity in children treated on investigational drug trials. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2011, 17:5982-5990.
14. Didierlaurent A.M., Morel S., Lockman L., Giannini S.L., Bisteau M., Carlsen H., et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. Journal of Immunology 2009, 183:6186-6197.
15. Peeling L., Hentschel S., Fox R., Hall H., Fourney D.R. Intraoperative spinal cord and nerve root monitoring: a survey of Canadian spine surgeons. Canadian Journal of Surgery Journal Canadien de Chirurgie 2010, 53:324-328.
16. Wack A., Baudner B.C., Hilbert A.K., Manini I., Nuti S., Tavarini S., et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 2008, 26:552-561.
17. Foxall P.J., Mellotte G.J., Bending M.R., Lindon J.C., Nicholson J.K. NMR spectroscopy as a novel approach to the monitoring of renal transplant function. Kidney International 1993, 43:234-245.
18. Mulcahy D., Keegan J., Fox K.M. Characteristics of silent and painful ischaemia during ambulatory monitoring in patients with coronary arterial disease. International Journal of Cardiology 1990, 28:377-379.
19. Fox N., Hirsch-Allen A.J., Goodfellow E., Wenner J., Fleetham J., Ryan C.F., et al. The impact of a telemedicine monitoring system on positive airway pressure adherence in patients with obstructive sleep apnea: a randomized controlled trial. Sleep 2012, 35:477-481.
20. Malyala P., Chesko J., Ugozzoli M., Goodsell A., Zhou F., Vajdy M., et al. The potency of the adjuvant, CpG oligos, is enhanced by encapsulation in PLG microparticles. Journal of Pharmaceutical Sciences 2008, 97:1155-1164.
21. Fox E., Jobsis-Vander Vliet F.F., Mitnick M.H. Monitoring cerebral oxygen sufficiency in anesthesia and surgery. Advances in Experimental Medicine and Biology 1985, 191:849-854.
22. Hem S.L., Hogenesch H. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Review of Vaccines 2007, 6:685-698.
23. Hem S.L., HogenEsch H., Middaugh C.R., Volkin D.B. Preformulation studies - the next advance in aluminum adjuvant-containing vaccines. Vaccine 2010, 28:4868-4870.
24. Baylor N.W., Egan W., Richman P. Aluminum salts in vaccines - US perspective. Vaccine 2002, 20(Suppl. 3):S18-S23.
25. Romero Mendez I.Z., Shi Y., HogenEsch H., Hem S.L. Potentiation of the immune response to non-adsorbed antigens by aluminum-containing adjuvants. Vaccine 2007, 25:825-833.
26. Kanra G., Viviani S., Yurdakok K., Ozmert E., Anemona A., Yalcin S., et al. Effect of aluminum adjuvants on safety and immunogenicity of Haemophilus influenzae type b-CRM197 conjugate vaccine. Pediatrics International: Official Journal of the Japan Pediatric Society 2003, 45:314-318.
27. Clapp T., Siebert P., Chen D., Jones Braun L. Vaccines with aluminum-containing adjuvants: optimizing vaccine efficacy and thermal stability. Journal of Pharmaceutical Sciences 2011, 100:388-401.
28. Jones L.S., Peek L.J., Power J., Markham A., Yazzie B., Middaugh C.R. Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens. Journal of Biological Chemistry 2005, 280:13406-13414.
29. Chang M.F., White J.L., Nail S.L., Hem S.L. Role of the electrostatic attractive force in the adsorption of proteins by aluminum hydroxide adjuvant. PDA Journal of Pharmaceutical Science and Technology/PDA 1997, 51:25-29.
30. Peek L.J., Martin T.T., Elk Nation C., Pegram S.A., Middaugh C.R. Effects of stabilizers on the destabilization of proteins upon adsorption to aluminum salt adjuvants. Journal of Pharmaceutical Sciences 2007, 96:547-557.
31. Hem S.L. Elimination of aluminum adjuvants. Vaccine 2002, 20(Suppl. 3):S40-S43.
32. Hansen B., Sokolovska A., HogenEsch H., Hem S.L. Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response. Vaccine 2007, 25:6618-6624.
33. Egan P.M., Belfast M.T., Gimenez J.A., Sitrin R.D., Mancinelli R.J. Relationship between tightness of binding and immunogenicity in an aluminum-containing adjuvant-adsorbed hepatitis B vaccine. Vaccine 2009, 27:3175-3180.
34. Hansen B., Belfast M., Soung G., Song L., Egan P.M., Capen R., et al. Effect of the strength of adsorption of hepatitis B surface antigen to aluminum hydroxide adjuvant on the immune response. Vaccine 2009, 27:888-892.
35. Hansen B., Malyala P., Singh M., Sun Y., Srivastava I., Hogenesch H., et al. Effect of the strength of adsorption of HIV 1 SF162dV2gp140 to aluminum-containing adjuvants on the immune response. Journal of Pharmaceutical Sciences 2011, 100:3245-3250.
36. Mitkus R.J., King D.B., Hess M.A., Forshee R.A., Walderhaug M.O. Updated aluminum pharmacokinetics following infant exposures through diet and vaccination. Vaccine 2011, 29:9538-9543.
37. Lipkin D.P., Perrins E.J., Shapiro L.M., Ludgate L., Fox K.M. Diagnosis of broad complex tachycardias with ambulatory monitoring of atrial electrography. British Medical Journal 1984, 288:1713-1714.
38. Vecchi S., Bufali S., Skibinski D.A., O'Hagan D.T., Singh M. Aluminum adjuvant dose guidelines in vaccine formulation for preclinical evaluations. Journal of Pharmaceutical Sciences 2012, 101:17-20.
39. Hu L., Joshi S.B., Andra K.K., Thakkar S.V., Volkin D.B., Bann J.G., et al. Comparison of the structural stability and dynamic properties of recombinant anthrax protective antigen and its 2-fluorohistidine-labeled analogue. Journal of Pharmaceutical Sciences 2012, 101(11):4118-4128. 10.1002/jps.23294.
40. Hu L., Joshi S.B., Liyanage M.R., Pansalawatta M., Alderson M.R., Tate A., et al. Physical characterization and formulation development of a recombinant pneumolysoid protein-based pneumococcal vaccine. Journal of Pharmaceutical Sciences 2013, 102:387-400.
41. Brewer J.M. (How) do aluminium adjuvants work. Immunology Letters 2006, 102:10-15.
42. HogenEsch H. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine 2002, 20(Suppl. 3):S34-S39.
43. Morefield G.L., Sokolovska A., Jiang D., HogenEsch H., Robinson J.P., Hem S.L. Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 2005, 23:1588-1595.
44. Goto N., Kato H., Maeyama J., Shibano M., Saito T., Yamaguchi J., et al. Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminium hydroxide with different physical properties. Vaccine 1997, 15:1364-1371.
45. Ulanova M., Tarkowski A., Hahn-Zoric M., Hanson L.A. The Common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infection and Immunity 2001, 69:1151-1159.
46. Sun H., Pollock K.G., Brewer J.M. Analysis of the role of vaccine adjuvants in modulating dendritic cell activation and antigen presentation in vitro. Vaccine 2003, 21:849-855.
47. Rimaniol A.C., Gras G., Verdier F., Capel F., Grigoriev V.B., Porcheray F., et al. Aluminum hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type. Vaccine 2004, 22:3127-3135.
48. Seubert A., Monaci E., Pizza M., O'Hagan D.T., Wack A. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. Journal of Immunology 2008, 180:5402-5412.
49. Jordan M.B., Mills D.M., Kappler J., Marrack P., Cambier J.C. Promotion of B cell immune responses via an alum-induced myeloid cell population. Science 2004, 304:1808-1810.
50. De Gregorio E., Tritto E., Rappuoli R. Alum adjuvanticity: unraveling a century old mystery. European Journal of Immunology 2008, 38:2068-2071.
51. Hodder E. Transfusion of milk in cholera. Practitioner 1873, 10:14.
52. Hippalgaonkar K., Majumdar S., Kansara V. Injectable lipid emulsions-advancements, opportunities and challenges. AAPS PharmSciTech 2010, 11:1526-1540.
53. Ott G., Radhakrishnan R., Fang J.-H., Hora M. The adjuvant MF59: a 10-year perspective. Vaccine Adjuvants 2000, 42:211-228.
54. Klucker M.F., Dalencon F., Probeck P., Haensler J. AF03, an alternative squalene emulsion-based vaccine adjuvant prepared by a phase inversion temperature method. Journal of Pharmaceutical Sciences 2012, 101:4490-4500.
55. O'Hagan D.T. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Review of Vaccines 2007, 6:699-710.
56. Podda A., Del Giudice G. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Review of Vaccines 2003, 2:197-203.
57. Vesikari T., Karvonen A., Tilman S., Borkowski A., Montomoli E., Banzhoff A., et al. Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence. Pediatrics 2010, 126:e762-e770.
58. Miller E., Andrews N., Stellitano L., Stowe J., Winstone A.M., Shneerson J., et al. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ 2013, 346:f794.
59. Nohynek H., Jokinen J., Partinen M., Vaarala O., Kirjavainen T., Sundman J., et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS ONE 2012, 7:e33536.
60. Partinen M., Saarenpaa-Heikkila O., Ilveskoski I., Hublin C., Linna M., Olsen P., et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS ONE 2012, 7:e33723.
61. Tsai T.F., Crucitti A., Nacci P., Nicolay U., Della Cioppa G., Ferguson J., et al. Explorations of clinical trials and pharmacovigilance databases of MF59(R)-adjuvanted influenza vaccines for associated cases of narcolepsy. Scandinavian Journal of Infectious Diseases 2011, 43:702-706.
62. Tsai T., Giudice G.D., Crucitti A., Weil J., Narasimhan V. Is the adjuvant solely to blame?. BMJ 2013, 346:f2375.
63. Mosca F., Tritto E., Muzzi A., Monaci E., Bagnoli F., Iavarone C., et al. Molecular and cellular signatures of human vaccine adjuvants. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:10501-10506.
64. Morel S., Didierlaurent A., Bourguignon P., Delhaye S., Baras B., Jacob V., et al. Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011, 29:2461-2473.
65. Stewart-Tull D. Freund's complete and incomplete adjuvants, preparation, and quality control standards for experimental laboratory animals use. Methods in Molecular Biology 2010, 5:9-72.
66. Stuewart-Tull D.E., Shimono T., Kotani S., Knights B.A. Immunosuppressive effect in mycobacterial adjuvant emulsions of mineral oils containing low molecular weight hydrocarbons. International Archives of Allergy and Applied Immunology 1976, 52:118-128.
67. Brito L.A., Chan M., Baudner B., Gallorini S., Santos G., O'Hagan D.T., et al. An alternative renewable source of squalene for use in emulsion adjuvants. Vaccine 2011, 29:6262-6268.
68. Fox C.B., Anderson R.C., Dutill T.S., Goto Y., Reed S.G., Vedvick T.S. Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions. Colloids and Surfaces B: Biointerfaces 2008, 65:98-105.
69. Fox C.B., Baldwin S.L., Duthie M.S., Reed S.G., Vedvick T.S. Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions. Vaccine 2011, 29:9563-9572.
70. Calabro S., Tritto E., Pezzotti A., Taccone M., Muzzi A., Bertholet S., et al. The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect. Vaccine 2013, pii: S0264-410X(13)00563-X.
71. O'Hagan D.T., Ott G.S., Nest G.V., Rappuoli R., Giudice G.D. The history of MF59((R)) adjuvant: a phoenix that arose from the ashes. Expert Review of Vaccines 2013, 12:13-30.
72. Hamouda T., Chepurnov A., Mank N., Knowlton J., Chepurnova T., Myc A., et al. Efficacy, immunogenicity and stability of a novel intranasal nanoemulsion-adjuvanted influenza vaccine in a murine model. Human Vaccines 2010, 6:585-594.
73. Hamouda T., Sutcliffe J.A., Ciotti S., Baker J.R. Intranasal immunization of ferrets with commercial trivalent influenza vaccines formulated in a nanoemulsion-based adjuvant. Clinical and Vaccine Immunology 2011, 18:1167-1175.
74. Stanberry L.R., Simon J.K., Johnson C., Robinson P.L., Morry J., Flack M.R., et al. Safety and immunogenicity of a novel nanoemulsion mucosal adjuvant W805EC combined with approved seasonal influenza antigens. Vaccine 2012, 30:307-316.
75. Boyce T.G., Hsu H.H., Sannella E.C., Coleman-Dockery S.D., Baylis E., Zhu Y., et al. Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults. Vaccine 2000, 19:217-226.
76. Barchfeld G.L., Hessler A.L., Chen M., Pizza M., Rappuoli R., Van Nest G.A. The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice. Vaccine 1999, 17:695-704.
77. GlaxoSmithKline Inc. Product information leaflet - Arepandrix H1N1 2003, http://www.gsk.ca/english/docs-pdf/Arepanrix_PIL_CAPA01v01.pdf.
78. GlaxoSmithKline Biologicals s.a. Summary of product characteristics 2009, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000832/WC500038121.pdf.
79. Adelmann H., Binks B.P., Mezzenga R. Oil powders and gels from particle-stabilized emulsions. Langmuir: The ACS Journal of Surfaces and Colloids 2012, 28:1694-1697.
80. Keefer M.C., Graham B.S., McElrath M.J., Matthews T.J., Stablein D.M., Corey L., et al. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59, NIAID AIDS Vaccine Evaluation Group. AIDS Research and Human Retroviruses 1996, 12:683-693.
81. Roestenberg M., Remarque E., de Jonge E., Hermsen R., Blythman H., Leroy O., et al. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. PLoS ONE 2008, 3:e3960.
82. Behzad H., Huckriede A.L., Haynes L., Gentleman B., Coyle K., Wilschut J.C., et al. GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults. Journal of Infectious Diseases 2012, 205:466-473.
83. Coler R.N., Baldwin S.L., Shaverdian N., Bertholet S., Reed S.J., Raman V.S., et al. A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS ONE 2010, 5:e13677.
84. Baldwin S.L., Bertholet S., Reese V.A., Ching L.K., Reed S.G., Coler R.N. The importance of adjuvant formulation in the development of a tuberculosis vaccine. Journal of Immunology 2012, 188:2189-2197.
85. (IDRI) IDRI AERAS and IDRI sign agreement to jointly develop novel tuberculosis vaccine 2012, Infectious Disease Research Institute (IDRI). http://www.idri.org/press-5-9-12.php.
86. Baudner B.C., Ronconi V., Casini D., Tortoli M., Kazzaz J., Singh M., et al. MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020). Pharmaceutical Research 2009, 26:1477-1485.
87. Shakeel F. Criterion for excipients screening in the development of nanoemulsion formulation of three anti-inflammatory drugs. Pharmaceutical Development and Technology 2010, 15:131-138.
88. Bangham A.D., Horne R.W. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. Journal of Molecular Biology 1964, 8:660-668.
89. Allison A.G., Gregoriadis G. Liposomes as immunological adjuvants. Nature 1974, 252:252.
90. Moon J.J., Suh H., Bershteyn A., Stephan M.T., Liu H., Huang B., et al. Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nature Materials 2011, 10:243-251.
91. Moon J.J., Suh H., Li A.V., Ockenhouse C.F., Yadava A., Irvine D.J. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:1080-1085.
92. D'Acremont V., Herzog C., Genton B. Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly. Journal of Travel Medicine 2006, 13:78-83.
93. Gluck R., Mischler R., Brantschen S., Just M., Althaus B., Cryz S.J. Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. Journal of Clinical Investigation 1992, 90:2491-2495.
94. Brady M.I., Furminger I.G. A surface antigen influenza vaccine. 1. Purification of haemagglutinin and neuraminidase proteins. Journal of Hygiene 1976, 77:161-172.
95. Renfrey S., Watts A. Morphological and biochemical characterization of influenza vaccines commercially available in the United Kingdom. Vaccine 1994, 12:747-752.
96. Korsholm K.S., Andersen P.L., Christensen D. Cationic liposomal vaccine adjuvants in animal challenge models: overview and current clinical status. Expert Review of Vaccines 2012, 11:561-577.
97. Lonez C., Vandenbranden M., Ruysschaert J.M. Cationic liposomal lipids: from gene carriers to cell signaling. Progress in Lipid Research 2008, 47:340-347.
98. Even-Or O., Samira S., Rochlin E., Balasingam S., Mann A.J., Lambkin-Williams R., et al. Immunogenicity, protective efficacy and mechanism of novel CCS adjuvanted influenza vaccine. Vaccine 2010, 28:6527-6541.
99. Davidsen J., Rosenkrands I., Christensen D., Vangala A., Kirby D., Perrie Y., et al. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate) - a novel adjuvant inducing both strong CMI and antibody responses. Biochimica et Biophysica Acta 2005, 1718:22-31.
100. Henriksen-Lacey M., Devitt A., Perrie Y. The vesicle size of DDA:TDB liposomal adjuvants plays a role in the cell-mediated immune response but has no significant effect on antibody production. Journal of Controlled Release: Official Journal of the Controlled Release Society 2011, 154:131-137.
101. Lay M., Callejo B., Chang S., Hong D.K., Lewis D.B., Carroll T.D., et al. Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone) increases antibody response, cellular immunity, and antigenically drifted protection. Vaccine 2009, 27:3811-3820.
102. Vandepapeliere P. Vaccine compositions comprising a saponin adjuvant. In: ORGANIZATION EP, editor; 2011.
103. Kensil C.R., Kammer R. QS-21: a water-soluble triterpene glycoside adjuvant. Expert Opinion on Investigational Drugs 1998, 7:1475-1482.
104. Agnandji S.T., Lell B., Soulanoudjingar S.S., Fernandes J.F., Abossolo B.P., Conzelmann C., et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. New England Journal of Medicine 2011, 365:1863-1875.
105. Agnandji S.T., Lell B., Fernandes J.F., Abossolo B.P., Methogo B.G., Kabwende A.L., et al. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. New England Journal of Medicine 2012, 367:2284-2295.
106. Jeffery H., Davis S.S., O'Hagan D.T. The preparation and characterization of poly(lactide-co-glycolide) microparticles. II. The entrapment of a model protein using a (water-in-oil)-in-water emulsion solvent evaporation technique. Pharmaceutical Research 1993, 10:362-368.
107. O'Hagan D.T., McGee J.P., Holmgren J., Mowat A.M., Donachie A.M., Mills K.H., et al. Biodegradable microparticles for oral immunization. Vaccine 1993, 11:149-154.
108. Krupitsky E., Nunes E.V., Ling W., Illeperuma A., Gastfriend D.R., Silverman B.L. Injectable extended-release naltrexone for opioid dependence. Lancet 2011, 378:665. [author reply 666].
109. Jain S., O'Hagan D.T., Singh M. The long-term potential of biodegradable poly(lactide-co-glycolide) microparticles as the next-generation vaccine adjuvant. Expert Review of Vaccines 2011, 10:1731-1742.
110. Singh M., Kazzaz J., Chesko J., Soenawan E., Ugozzoli M., Giuliani M., et al. Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B. Journal of Pharmaceutical Sciences 2004, 93:273-282.
111. Singh M., Chesko J., Kazzaz J., Ugozzoli M., Kan E., Srivastava I., et al. Adsorption of a novel recombinant glycoprotein from HIV (Env gp120dV2 SF162) to anionic PLG microparticles retains the structural integrity of the protein, whereas encapsulation in PLG microparticles does not. Pharmaceutical Research 2004, 21:2148-2152.
112. Malyala P., O'Hagan D.T., Singh M. Enhancing the therapeutic efficacy of CpG oligonucleotides using biodegradable microparticles. Advanced Drug Delivery Reviews 2009, 61:218-225.
113. Kazzaz J., Singh M., Ugozzoli M., Chesko J., Soenawan E., O'Hagan D.T. Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency. Journal of Controlled Release: Official Journal of the Controlled Release Society 2006, 110:566-573.
114. Singh M., Kazzaz J., Ugozzoli M., Baudner B., Pizza M., Giuliani M., et al. MF59 oil-in-water emulsion in combination with a synthetic TLR4 agonist (E6020) is a potent adjuvant for a combination Meningococcus vaccine. Human Vaccines & Immunotherapeutics 2012, 8:486-490.
115. Jain S., Malyala P., Pallaoro M., Giuliani M., Petersen H., O'Hagan D.T., et al. A two-stage strategy for sterilization of poly(lactide-co-glycolide) particles by gamma-irradiation does not impair their potency for vaccine delivery. Journal of Pharmaceutical Sciences 2011, 100:646-654.
116. Whiton R.S., Lau P., Morgan S.L., Gilbart J., Fox A. Modifications in the alditol acetate method for analysis of muramic acid and other neutral and amino sugars by capillary gas chromatography-mass spectrometry with selected ion monitoring. Journal of Chromatography 1985, 347:109-120.
117. Bell K.J., Hayen A., Macaskill P., Craig J.C., Neal B.C., Fox K.M., et al. Monitoring initial response to angiotensin-converting enzyme inhibitor-based regimens: an individual patient data meta-analysis from randomized, placebo-controlled trials. Hypertension 2010, 56:533-539.
118. Aichinger M.C., Ginzler M., Weghuber J., Zimmermann L., Riedl K., Schutz G., et al. Adjuvating the adjuvant: facilitated delivery of an immunomodulatory oligonucleotide to TLR9 by a cationic antimicrobial peptide in dendritic cells. Vaccine 2011, 29:426-436.
119. Lingnau K., Riedl K., von Gabain A. IC31 and IC30, novel types of vaccine adjuvant based on peptide delivery systems. Expert Review of Vaccines 2007, 6:741-746.
120. Janeway C.A. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harbor Symposia on Quantitative Biology 1989, 54(Pt 1):1-13.
121. Ott G., Fang J.H., Hora M., Rademacker J.H. The adjuvant MF59: a 10-year perspective. Methods in Molecular Biology 2000, 42:211-228.
122. Garcon N., Vaughn D.W., Didierlaurent A.M. Development and evaluation of AS03, an Adjuvant System containing alpha-tocopherol and squalene in an oil-in-water emulsion. Expert Review of Vaccines 2012, 11:349-366.
123. Cox M. Update on clinical trials evaluation of adjuvanted fHA (H5) vaccines. 7th WHO meeting on evaluation of pandemic influenza vaccines in clinical trials 2011.